Events | 2018.02.08
Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology
THOUSAND OAKS, Calif., Feb. 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the XGEVA® (denosumab) Phase 3 \'482 study, the largest international multiple myeloma trial for the prevention of skeletal-related events ever conducted (n=1,718), were published in The...
For more information, please visit
https://www.prnewswire.com/news-releases[...]lancet-oncology-300596245.html
